- Thermo Fisher Scientific Inc TMO has posted Q3 revenue of $10.68 billion, up 14% Y/Y, including a 14% core organic revenue growth, beating the consensus of $9.92 billion.
- Organic revenue growth was down 1%, acquisitions increased revenue by 20%, and currency translation decreased revenue by 5%.
- COVID-19 testing revenue was $0.44 billion.
- Revenue from Life Sciences Solutions Segment declined 20.4% to $2.96 billion. Analytical Instruments Segment sales were up 9.8% to $1.62 billion. Specialty Diagnostics Segment revenues decreased by 21.8% to $1.065 billion, and Laboratory Products and Biopharma Services segment sales were up 60% to $5.58 billion.
- Adjusted EPS of $5.08 topped the consensus of $4.82.
- Adjusted operating margin contracted from 29.8% to 22.2%.
- Price Action: TMO shares are up 4.93% at $539.99 during the premarket session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
